OnKure Therapeutics (OKUR) Enterprise Value (2021 - 2026)

OnKure Therapeutics (OKUR) has reported Enterprise Value for 6 consecutive years, with $8.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 115.7% year-over-year to $8.3 million; the trailing twelve-month figure through Jun 2026 stood at $8.3 million (up 115.7% YoY), and the FY2025 full-year result was -$19.4 million, down 587.97% from the prior year.
• Enterprise Value climbed to $8.3 million in Q2 2026 per OKUR's latest filing, from -$135.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at $890.2 million in Q3 2023 and bottomed at -$135.5 million in Q1 2026.
• Historically, Enterprise Value has averaged $130.8 million across 5 years, with a median of -$7.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 685.01% in 2022, then jumped 2725.47% in 2023.
• Over 5 years, Enterprise Value stood at -$43.6 million in 2022, then soared by 348.03% to $108.2 million in 2023, then sank by 96.32% to $4.0 million in 2024, then tumbled by 587.97% to -$19.4 million in 2025, then soared by 142.56% to $8.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $8.3 million, -$135.5 million, and -$19.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.